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Open access under the ElseviHigh-grade prostate cancers express high levels of matrix metalloproteinases (MMPs), major enzymes
involved in tumor invasion and metastasis. However, the tumor cell lines commonly employed for pros-
tate cancer research express only small amounts of MMPs when cultivated as monolayer cultures, in
common culture media. The present study was conducted to ascertain whether culture conditions that
include ﬁbronectin can alter MMP2 and MMP9 expression by the human prostatic epithelial cell lines
RWPE-1, LNCaP and PC-3. These cells were individually seeded at 2  104 cells/cm2, cultivated until they
reached 80% conﬂuence, and then exposed for 4 h to ﬁbronectin, after which the conditioned medium
was analyzed by gelatin zymography. Untreated cells were given common medium. Only RWPE-1 cells
express detectable amounts of MMP9 when cultivated in common medium, whereas the addition of
ﬁbronectin induced high expression levels of pro and active forms of MMP2 in all tested cell lines. Our
ﬁndings demonstrate that normal and tumor prostate cell lines express MMP2 activity when in contact
with extracellular matrix components or blood plasma proteins such as ﬁbronectin. Future studies of
transcriptomes and proteomes in prostate cancer research using these cell lines should not neglect these
important conclusions.
 2012 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Prostate cancer is the most commonmalignancy in men and the
second leading cause of male cancer-related deaths in the Western
world [1,2]. Castration-resistant prostate cancer (CRPC) is the most
advanced form of prostate cancer exhibiting reduced survival, with
reported values varying between 9 and 30 months [2]. In this
sense, in vitro culture systems are widely employed in prostate
cancer research and, more recently, for transcriptome and proteo-
mic analysis because the cultures reproduce rapidly and readily
[3]. Although these monolayer cultures provide rapid and impor-
tant results, they recreate only a fraction of a complex scenario
[4]. The absence of cell-to-extracellular matrix (ECM) interactions
can lead to misleading results, especially for prostate cancer, where
the cross-signaling between epithelium and stroma is so important
[5].
Matrix metalloproteinase’s (MMPs) belong to a family of zinc
and calcium dependant endopeptidases responsible for the ﬁrst
steps in ECM degradation in both normal development and
disease [6,7]. A very invasive and metastatic behavior is a majoraulista – UNESP, Institute of
lar Matrix Lab., District of
x: +55 1438800502.
er OA license. characteristic of CRPC, and ECM degradation is critical to these
processes [2,7]. However, the commonly employed tumoral cell
lines on prostate cancer research express small amounts of MMPs
when cultivated in monolayer cultures with common culture
media [8,9], without ECM components.
Considering that cell-ECM cross-talk, when present in culture
systems, leads to behavioral changes in tumor cell biology, such
as increased adherence to substrates [10], increased resistance to
chemotherapeutic agents [11], and resistance to apoptosis [12],
we hypothesized that it could also modulate the expression of
MMPs by human prostate cells. Therefore, we conducted the pres-
ent investigation exposing the classical human prostate cell lines
RWPE-1, LNCaP, and PC-3 to ﬁbronectin, a multifunctional extra-
cellular glycoprotein, which is considered of critical relevance for
the process of metastasis and cell survival [13]. Not only is ﬁbro-
nectin the most abundant adhesion protein in the blood, but it also
interacts with circulating tumor cells [13], and therefore the ECM
protein chosen for this investigation.
Furthermore, employing this culture model, we exposed these
cells to ﬁnasteride, an inhibitor of the enzyme ﬁve alpha-reductase,
which is widely used in benign prostatic hyperplasia treatment
and potentially a chemopreventive agent for prostate cancer [14],
to ascertain whether in these conditions ﬁnasteride would also
modulate the expression of MMP2, as previously reported for the
rat ventral prostate [15], where epithelial-stroma interactions
occur.
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RWPE-1, LNCaP, and PC-3 cell lines were acquired from the
American Type Culture Collection (ATCC). The experiments were
performed two months after the acquisition of the cell lines, which
were cultivated according to ATCC guidelines. These cells were
then individually seeded at 2  104 cells/cm2 in 6-well culture
plates (TPP™) and the experiments were carried out in triplicate.
Upon reaching 80% conﬂuence, cells were washed three times with
sterile D-PBS (GIBCO/Invitrogen™), and the recommended culture
medium (FBS free) was added as follows: (1) control treatment –
0.1% dimethylsulfoxide (DMSO); (2) ﬁbronectin treatment – 0.1%
DMSO plus 25 lg/mL ﬁbronectin (Sigma™); and (3) combined
ﬁbronectin/ﬁnasteride treatment – 0.1% DMSO plus 25 lg/mL
ﬁbronectin (Sigma™) plus 50 lM ﬁnasteride (Sigma™). All re-
agents were dissolved in the culture medium. After 4 h of expo-
sure, the conditioned media (CM) were collected and individually
stored at 80 C.
The CM were concentrated using Centriprep 10,000 MWCO
(Millipore™) tubes and submitted to protein quantiﬁcation at a
NanoDrop 2000 (Thermo Scientiﬁc™) spectrophotometer. Equal
amounts of protein from CM (15 lg) were analyzed by gelatin
zymography on 8% polyacrylamide gels co-polymerized with
0.1% gelatin (Merck™) as substrate. Puriﬁed human MMP2
(20 ng) and MMP9 (30 pg) (Calbiochem™) were also loaded as po-
sitive controls. After electrophoresis, the gels were rinsed twice in
2.5% Triton X-100 and incubated 24 h in an activation buffer
(50 mM Tris–HCl, 5 mM CaCl2 and 0.02% ZnCl2). Gels were stained
with Coomassie brilliant blue R-250 and de-stained with 20%
methanol and 10% acetic acid in distilled water until the clear
bands had been visualized. The activities of the MMP2 and
MMP9 bands were quantiﬁed using the ImageJ™ software for each
sample (as triplicates). The integrated optical density (IOD) wasFig. 1. (A) Representative zymography of the gelatinolytic activity observed in the condit
plus ﬁnasteride treated cells (Ff). Lane S corresponds to the reference standard of human
were observed, which correspond to pro-MMP9, active-MMP9, pro-MMP2, and active-M
activity. Fibronectin treatment induced high MMP2 activity in all tested cell lines. Fi
expresses mainly pro-MMP2, whereas PC-3 expresses active-MMP2 after ﬁbronectin tre
media from untreated, ﬁbronectin treated and ﬁbronectin/ﬁnasteride treated cells (RWPE
MMP2 total band IOD between the ﬁbronectin and combined ﬁbronectin/ﬁnasteride t
treatment signiﬁcantly increased MMP2 activity in the three cell lines, whereas ﬁnaster
signiﬁcant difference from untreated cells with p < 0.001. ⁄⁄Statistically signiﬁcant differmeasured and the data were analyzed with INSTAT™ software
using the two tail Student’s t test (p < 0.05) to compare the differ-
ent treatments. Values were calculated as the mean ± SD of the
totality of IODs for the pro- and active forms of the MMP2 and
MMP9 enzymes. Finally, a fold-change graphic was made by divid-
ing the means of the values for the treated cells by the mean of the
values for the untreated cells.
3. Results
When cultivated in common culture media, all cell lines pro-
duced very low detectable levels of MMP2 activity (Fig. 1A). Fibro-
nectin exposure signiﬁcantly upregulated MMP2 activity in all
three cell lines, with a 25.5-fold-change in RWPE-1 cells, a 22.6-
fold-change in the LNCaP cells and a 24.0-fold-change in PC-3 cells
compared with controls (Fig. 1B). However, when these cell lines
were co-exposed to ﬁbronectin and ﬁnasteride, the activity of
MMP2 was signiﬁcantly lower than those treated only with ﬁbro-
nectin; reduced at least by 33% (Fig. 1B).
Curiously, the LNCaP cells primarily expressed pro-MMP2
whereas PC-3 expressed active-MMP2 (Fig. 1A), a phenomenon
most likely related to the greater invasive behavior of PC-3. In con-
trast, only RWPE-1 cells expressed low but detectable amounts of
MMP9, mostly in its pro-form (Fig. 1A). Fibronectin treatment in-
duced partial activation of MMP9, whereas ﬁnasteride reduced this
activation (Fig. 1A) (p > 0.05).
4. Discussion
In this study, we evaluated the expression of gelatinases A and B
in the prostate cells lines RWPE-1, LNCaP and PC-3, which are
widely employed in prostate cancer research, using two different
culture conditions. In our initial experiments, we demonstratedioned medium from untreated cells (U), ﬁbronectin-treated cells (F), and ﬁbronectin
active-MMP9 and pro-MMP2 enzymes. Gelatinolytic bands of 92, 81, 72, and 62 kDa
MP2, respectively. In normal culture conditions only RWPE-1 cells express MMP9
nasteride-treatment signiﬁcantly downregulated this induction. Note that LNCaP
atment. (B) Densitometry analysis of the gelatinolytic bands from the conditioned
-1, LNCaP and PC-3). The data are expressed as the fold-change of the means ± SD of
reatments over the untreated cells, which were given the value of 1. Fibronectin
ide treatment signiﬁcantly reduced total MMP2 gelatinolytic activity. ⁄Statistically
ence from ﬁbronectin treated cells with p < 0.05.
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culture medium, all of them secreted very low amounts of MMPs in
their CM, in accordance to previous results [8,9]. Interestingly, only
the non-tumoral cell line RWPE-1 expressed detectable levels of
MMP9 under these culture conditions. However, when the cell cul-
tures were grown with ﬁbronectin in the culture medium, all the
cell lines tested exhibited signiﬁcantly higher MMP2 levels in their
CM. Although this effect was observed for MMP2 in all tested cell
lines, this was not observed for MMP9. Furthermore, our results
demonstrated that the co-treatment of these cells, with ﬁbronectin
and ﬁnasteride, resulted in the same pattern of downregulation of
MMP2 activity after ﬁnasteride treatment, as observed in the rat
ventral prostate [15], and now reproduced in an in vitro model of
human prostate cancer.
Although Das et al. [16] reported higher expression of MMPs-2
and 9 upon exposure of human breast cancer cells to ﬁbronectin,
and Meng et al. [17] reported increased invasion of lung cancer
cells through MMP9 activity after ﬁbronectin treatment, this is
the ﬁrst report of enhanced activity of MMPs in prostate cancer cell
lines after ﬁbronectin exposure. Our ﬁndings highlight the impor-
tance of cell-ECM interactions in the modulation of these endopep-
tidases. Similar results were obtained by Pentyala et al. [18], who
showed that the interaction of LNCaP cells with the extracellular
matrix plays a dominant role in uPA and uPAR gene expression, an-
other protease system involved in ECM degradation [19].
Fibronectin has been shown to support cell proliferation and
invasion, which are major events for metastasis, and to protect tu-
moral cells from the cytotoxic action of natural killer cells [13].
Now we have demonstrated that ﬁbronectin can also upregulate
the expression of MMPs that are directly involved in prostate can-
cer aggressiveness. Interestingly, our ﬁndings demonstrated that
ﬁbronectin could only induce MMP2 activity, but not MMP9, in
the tested prostate cell lines. Although MMP2 has been historically
considered a constitutive gene due to the absence of well-charac-
terized regulatory elements in the MMP2 promoter region [20], re-
cent reports on MMP2 promoter analyses have demonstrated
numerous regulatory elements that could modulate MMP2 expres-
sion [21]. The mechanism by which ﬁbronectin induces MMP2
expression has been described in MCF-7 human breast carcinoma
cells and A549 human lung cancer cells, and involves ﬁbronec-
tin–integrin a5b1 interaction and/or FAK/PI-3K/ERK signaling
pathways activation [16,17], but this mechanism remains to be
conﬁrmed for prostate cancer cells, in future studies.
Taken together, all these reports highlight the importance of the
cell-ECM interactions for studying transcriptomes and proteomes
from both normal and tumoral cells, at in vitro systems [3–5,8–
10,13,16–18]. In this sense, future investigators should be aware
that RWPE-1, LNCaP and PC-3 cells, and most likely other tumor
cells, require cell-ECM interaction in order to express detectable
levels of MMPs on their CM.
In conclusion, our results conﬁrm that: (1) ﬁbronectin exposure
upregulates the activity of MMP2 in all tested human prostate cell
lines up to a 25-fold-increase and (2) by employing a human cell
culture model with cell-ECM interaction, it was possible to repro-
duce previous results of an in vivo study where ﬁnasteride down-
regulated the activity of MMP2 in the rat ventral prostate.Acknowledgments
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